-DOCSTART- -X- O
[ -X- _ O
Image -X- _ O
: -X- _ O
see -X- _ O
text -X- _ O
] -X- _ O
Small -X- _ O
interfering -X- _ O
RNA -X- _ O
( -X- _ O
siRNA -X- _ O
) -X- _ O
-based -X- _ O
therapies -X- _ O
have -X- _ O
great -X- _ O
promise -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
prevalent -X- _ O
pulmonary -X- _ O
disorders -X- _ O
including -X- _ O
lung -X- _ O
cancer -X- _ O
, -X- _ O
asthma -X- _ O
and -X- _ O
cystic -X- _ O
fibrosis. -X- _ O
However -X- _ O
, -X- _ O
progress -X- _ O
in -X- _ O
this -X- _ O
area -X- _ O
has -X- _ O
been -X- _ O
hindered -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
lack -X- _ O
of -X- _ O
carriers -X- _ O
that -X- _ O
can -X- _ O
efficiently -X- _ O
deliver -X- _ O
siRNA -X- _ O
to -X- _ O
lung -X- _ O
epithelial -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
also -X- _ O
due -X- _ O
to -X- _ O
challenges -X- _ O
in -X- _ O
developing -X- _ O
oral -X- _ O
inhalation -X- _ O
( -X- _ O
OI -X- _ O
) -X- _ O
formulations -X- _ O
for -X- _ O
the -X- _ O
regional -X- _ O
administration -X- _ O
of -X- _ O
siRNA -X- _ O
and -X- _ O
their -X- _ O
carriers -X- _ O
to -X- _ O
the -X- _ O
lungs. -X- _ O
In -X- _ O
this -X- _ O
work -X- _ O
we -X- _ O
report -X- _ O
the -X- _ O
ability -X- _ O
of -X- _ O
generation -X- _ O
four -X- _ O
, -X- _ O
amine-terminated -X- _ B-Intervention
poly -X- _ I-Intervention
( -X- _ I-Intervention
amidoamine -X- _ I-Intervention
) -X- _ I-Intervention
( -X- _ I-Intervention
PAMAM -X- _ I-Intervention
) -X- _ I-Intervention
dendrimer -X- _ I-Intervention
( -X- _ I-Intervention
G4NH2 -X- _ I-Intervention
) -X- _ I-Intervention
–siRNA -X- _ I-Intervention
complexes -X- _ I-Intervention
( -X- _ I-Intervention
dendriplexes -X- _ I-Intervention
) -X- _ I-Intervention
to -X- _ O
silence -X- _ O
the -X- _ O
enhanced -X- _ O
green -X- _ O
fluorescent -X- _ O
protein -X- _ O
( -X- _ O
eGFP -X- _ O
) -X- _ O
gene -X- _ O
on -X- _ O
A549 -X- _ O
lung -X- _ O
alveolar -X- _ O
epithelial -X- _ O
cells -X- _ O
stably -X- _ O
expressing -X- _ O
eGFP. -X- _ O
We -X- _ O
also -X- _ O
report -X- _ O
the -X- _ O
formulation -X- _ O
of -X- _ O
the -X- _ O
dendriplexes -X- _ B-Intervention
and -X- _ O
their -X- _ O
aerosol -X- _ O
characteristics -X- _ O
in -X- _ O
propellant-based -X- _ O
portable -X- _ O
OI -X- _ O
devices. -X- _ O
The -X- _ O
size -X- _ B-Outcome
and -X- _ I-Outcome
gene -X- _ I-Outcome
silencing -X- _ I-Outcome
ability -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
dendriplexes -X- _ I-Outcome
was -X- _ I-Outcome
seen -X- _ I-Outcome
not -X- _ I-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
a -X- _ I-Outcome
strong -X- _ I-Outcome
function -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
N -X- _ I-Outcome
/ -X- _ I-Outcome
P -X- _ I-Outcome
ratio. -X- _ I-Outcome
Silencing -X- _ O
efficiencies -X- _ O
of -X- _ O
up -X- _ O
to -X- _ O
40 -X- _ O
% -X- _ O
are -X- _ O
reported. -X- _ O
Stable -X- _ O
dispersions -X- _ O
of -X- _ O
the -X- _ O
dendriplexes -X- _ O
encapsulated -X- _ O
in -X- _ O
mannitol -X- _ O
and -X- _ O
also -X- _ O
in -X- _ O
a -X- _ O
biodegradable -X- _ O
and -X- _ O
water-soluble -X- _ O
co- -X- _ O
oligomer -X- _ O
were -X- _ O
prepared -X- _ O
in -X- _ O
hydrofluoroalkane -X- _ O
( -X- _ O
HFA -X- _ O
) -X- _ O
-based -X- _ O
pressurized -X- _ O
metered-dose -X- _ O
inhalers -X- _ O
( -X- _ O
pMDIs -X- _ O
) -X- _ O
. -X- _ O
Their -X- _ O
aerosol -X- _ O
characteristics -X- _ O
were -X- _ O
very -X- _ O
favorable -X- _ O
, -X- _ O
and -X- _ O
conducive -X- _ B-Outcome
to -X- _ I-Outcome
deep -X- _ I-Outcome
lung -X- _ I-Outcome
deposition -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
respirable -X- _ I-Outcome
fractions -X- _ I-Outcome
of -X- _ I-Outcome
up -X- _ I-Outcome
to -X- _ I-Outcome
77 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ O
Importantly -X- _ O
, -X- _ O
siRNA -X- _ B-Outcome
formulated -X- _ I-Outcome
as -X- _ I-Outcome
dendriplexes -X- _ I-Outcome
in -X- _ I-Outcome
pMDIs -X- _ I-Outcome
was -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
keep -X- _ I-Outcome
its -X- _ I-Outcome
integrity -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
particle -X- _ I-Outcome
preparation -X- _ I-Outcome
processes -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
also -X- _ I-Outcome
after -X- _ I-Outcome
long-term -X- _ I-Outcome
exposures -X- _ I-Outcome
to -X- _ I-Outcome
HFA. -X- _ I-Outcome
The -X- _ O
relevance -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
stems -X- _ O
from -X- _ O
the -X- _ O
fact -X- _ O
that -X- _ O
this -X- _ O
is -X- _ O
the -X- _ O
first -X- _ O
work -X- _ O
to -X- _ O
report -X- _ O
the -X- _ O
formulation -X- _ O
of -X- _ O
inhalable -X- _ O
siRNA -X- _ O
with -X- _ O
aerosol -X- _ O
properties -X- _ O
suitable -X- _ O
to -X- _ O
deep -X- _ O
lung -X- _ O
deposition -X- _ O
using -X- _ O
pMDIs -X- _ O
devices -X- _ O
that -X- _ O
are -X- _ O
the -X- _ O
least -X- _ O
expensive -X- _ O
and -X- _ O
most -X- _ O
widely -X- _ O
used -X- _ O
portable -X- _ O
inhalers. -X- _ O
This -X- _ O
study -X- _ O
is -X- _ O
relevant -X- _ O
because -X- _ O
, -X- _ O
also -X- _ O
for -X- _ O
the -X- _ O
first -X- _ O
time -X- _ O
, -X- _ O
it -X- _ O
shows -X- _ O
that -X- _ O
siRNA–G4NH2 -X- _ B-Outcome
dendriplexes -X- _ I-Outcome
can -X- _ I-Outcome
efficiently -X- _ I-Outcome
target -X- _ I-Outcome
lung -X- _ I-Outcome
alveolar -X- _ I-Outcome
epithelial -X- _ I-Outcome
A549 -X- _ I-Outcome
cells -X- _ I-Outcome
and -X- _ I-Outcome
silence -X- _ I-Outcome
genes -X- _ I-Outcome
even -X- _ I-Outcome
after -X- _ I-Outcome
siRNA -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
exposed -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
propellant -X- _ I-Outcome
environment -X- _ I-Outcome
. -X- _ O

